News

December 19, 2017

Juno, Celgene Report Impressive Results of CAR T-cell Therapy in B-cell Lymphoma

News

The CAR T-cell therapy JCAR017, developed by Juno Therapeutics and Celgene, eradicated B-cell lymphomas in more than two-thirds of patients with high-risk cancer, the companies announced. The response to the ... Read more

December 18, 2017

Rhizen’s Tenalisib Receives FDA Fast Track Status for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the tenalisib (RP6530), Rhizen Pharmaceuticals‘ PI3K delta/gamma blocker, for the treatment of patients with relapsed or refractory peripheral ... Read more

December 15, 2017December 15, 2017

FDA Reviews Application for Keytruda in Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) agreed to review Merck’s application to add relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL) to the list of cancers treated with ... Read more

December 14, 2017December 14, 2017

5-Year Survival Rates Promising for MTLC Patients Treated with Adcetris in Phase 1 Trial

News

Seattle Genetics reported promising five-year survival results from its Phase 1 clinical trial of Adcetris (brentuximab vedotin) in mature T-cell lymphoma (MTCL), also known as peripheral T-cell lymphoma. The findings ... Read more

December 13, 2017

40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta

News

More than a year after receiving the CAR T-cell therapy Yescarta (axicabtagene ciloleucel), 42 percent of the patients in the ZUMA-1 trial are still responding to the treatment, Kite Pharma announced. The Phase ... Read more

December 12, 2017December 12, 2017

Immune Response to Reactive Herpes Virus Tied to Graft-versus-host Disease in Transplant Patients in Study

News

The immune system’s response to reactivated human cytomegalovirus (hCMV) infection, a form of herpes virus, has been linked to the onset of graft-versus-host disease (GVHD). The discovery, made by a ... Read more

December 11, 2017

Aptevo to Launch Phase 2 Trial of Therapy Candidate for Peripheral T-cell Lymphoma

News

Aptevo Therapeutics, a biotech company developing new therapies for blood and lymph cancers, will soon launch a Phase 2 clinical trial to evaluate its monospecific antibody candidate, otlertuzumab, in patients ... Read more

December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more

December 7, 2017

Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show

News

Adding the investigational treatment polatuzumab vedotin to a therapy of Bendeka (bendamustine) and Rituxan (rituximab) made patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) respond better to the ... Read more

December 6, 2017December 6, 2017

TRPH-222 Shows Significant Anti-tumor Activity in Lymphoma Preclinical Models

News

An investigational antibody-drug conjugate, TRPH-222, effectively reduced tumor burden in mice with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), and is well-tolerated in non-human primates, a new ... Read more